Status:
RECRUITING
Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS
Lead Sponsor:
Dr. med. Christian Rothermundt
Collaborating Sponsors:
German Testicular Cancer Study Group
Conditions:
Testicular Neoplasms
Eligibility:
MALE
18+ years
Brief Summary
The majority of testicular cancer patients can be cured with cisplatin-based chemotherapy. Mortality has been reduced even more within the last 15 years due to the stringent application of standard ch...
Detailed Description
Objectives Primary objective The primary objective is to determine the diagnostic performance and the clinical impact of a variety of tests, including conventional radiographs, computer tomographies...
Eligibility Criteria
Inclusion
- Written informed consent.
- Histologically proven seminomas or non-seminoma.
- Seminoma: complete remission (CR) or lymph nodes (LN) \< 3cm or PET negative partial remission (PR) or non-seminoma: CR.
- Completion of treatment within the last 6 months.
- Patient able and willing to attend for regular surveillance.
Exclusion
- Co-existent malignancy within 5 years.
- Inability for any reason to comply with the trial investigations or follow-up schedules.
Key Trial Info
Start Date :
December 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2033
Estimated Enrollment :
6900 Patients enrolled
Trial Details
Trial ID
NCT02229916
Start Date
December 1 2013
End Date
December 1 2033
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital St.Gallen; Onkologie/Haematologie
Sankt Gallen, Switzerland, 9007